AH

DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021

Retrieved on: 
Monday, November 8, 2021
Mortality, Safety, American Association, Fast track (FDA), Boxed warning, Fatty liver disease, Clinical trial, SABER, Technology, Food, AASLD, Institute of Liver and Biliary Sciences, COVID-19, Publication, Risk, Association, Liver, Chronic liver disease, Company, NASH, Review, DNA, Poster, Prevalence, Patient, Fast Track, FDA, American Association for the Study of Liver Diseases, AH, Pharmaceutical industry

CUPERTINO, Calif., Nov. 8, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D.

Key Points: 
  • CUPERTINO, Calif., Nov. 8, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D.
  • will present a poster at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2021 to be held virtuallyNovember 12-15, 2021.
  • The E-Poster will provide data on recent prevalence, co-morbidities, and mortality in hospitalized alcohol-associated hepatitis (AH) patients in the U.S. using the most recent Nationwide Inpatient Sample data from 2015-2018.
  • The e-Poster will be available on the DURECT website under "DUR-928 Publications" here: DURECT | DUR-928 Publications following the conclusion of the conference.

DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2

Retrieved on: 
Tuesday, October 26, 2021
Safety, Non-alcoholic fatty liver disease, Technology, Patient, FDA, View, Food, AH, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Boxed warning, Company, Clinical trial, COVID-19, Chronic liver disease, Multimedia, SABER, NASH, Pharmaceutical industry

DUR-928, the Company's lead drug candidate, is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation.

Key Points: 
  • DUR-928, the Company's lead drug candidate, is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation.
  • Non-alcoholic steatohepatitis (NASH) is also being explored.In addition, POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER platform technology,is now FDA-approved.
  • Full prescribing information about POSIMIR, including the Boxed Warning, can be found at www.posimir.com .
  • Further information regarding these and other risks is included in DURECT's Form 10-Q filed on July 30, 2021 under the heading "Risk Factors."

DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference

Retrieved on: 
Thursday, October 7, 2021
Company, Technology, Risk, COVID-19, Food, Multimedia, Calendar, Safety, Boxed warning, SABER, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Non-alcoholic fatty liver disease, Chronic liver disease, AH, Patient, Clinical trial, View, NASH, Pharmaceutical industry

Management will also be available for virtual 1x1 meetings during the conference.

Key Points: 
  • Management will also be available for virtual 1x1 meetings during the conference.
  • If attendees would like to request a meeting, please contact H.C. Wainwright directly.
  • Non-alcoholic steatohepatitis (NASH) is also being explored.In addition, POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER platform technology,is now FDA-approved.
  • NOTE: POSIMIR and SABER are trademarks of DURECT Corporation.

Atlanta Housing & HUD partner with The Family Health Centers of Georgia, Inc. to provide Free COVID-19 Vaccinations & Testing to Atlanta’s Housing Communities

Retrieved on: 
Thursday, October 7, 2021
Social media, Partnership, HUD, Atlanta Housing Authority, United States Department of Housing and Urban Development, Health, Transport, AH, FREE, Population, United States Department of Health and Human Services, Brooks, CEO, Family, COVID-19, Housing, African Americans, Vaccination, GLOBE, Pharmaceutical industry

Atlanta Housing is proud to work with The Family Health Centers of Georgia to advance the critically important cause of getting everyone in our communities vaccinated, said Eugene E. Jones, Jr., CEO of Atlanta Housing.

Key Points: 
  • Atlanta Housing is proud to work with The Family Health Centers of Georgia to advance the critically important cause of getting everyone in our communities vaccinated, said Eugene E. Jones, Jr., CEO of Atlanta Housing.
  • Focusing on those in our communities who are hesitant and providing them with the right information will literally save lives, Jones said.
  • FHCGA, in partnership with the Atlanta Housing, has provided free vaccinations to more than 600 senior residents to date.
  • Access to FREE COVID-19 answers, vaccination (with qualifying transportation) and testing are one call 1-800-935-6721 or one click away covid.fhcga.org .

Acquired Hemophilia Treatment Market 2021 to 2029: Increasing Prevalence of AH among New Born Demands Effective Treatment - ResearchAndMarkets.com

Retrieved on: 
Friday, October 1, 2021
Health, Pharmaceutical, Adoption, Rheumatoid arthritis, Mortality, Ferring Pharmaceuticals, FastTrack, Muscle, Neoplasm, Research, Genentech, CAGR, Biogen, Cancer, Patient, GlaxoSmithKline, Pregnancy, AH, Development, Novo Nordisk, Bristol Myers Squibb, CSL Behring, VIII, Antibody, Psoriasis, Growth, Prevalence, Awareness, Key, Pfizer, Research and development, Factor VIII, Ulcerative colitis, Bleeding, Haemophilia B, Haemophilia, Drug discovery, Haemophilia A, EMA, Skin, Bayer, Disorder, Marketing, Birth control, Pharmaceutical industry

The "Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The Acquired Hemophilia Treatment Market is anticipated to grow at a compound annual growth rate of 3.3% for the forecast period of 2021 to 2029.
  • The body produces inhibitors (antibodies) that target clotting factors, most commonly factor VIII, in Acquired Hemophilia.
  • On the basis of regional segmentation, Acquired Hemophilia Treatment Market includes North America, Latin America, Europe, Asia Pacific, Middle East and Africa, and Rest of the World.

DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021

Retrieved on: 
Thursday, September 23, 2021
Food, Clinical trial, Non-alcoholic fatty liver disease, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Patient, Boxed warning, AH, NASH, Company, Chronic liver disease, SABER, COVID-19, Technology, Safety, Calendar, Pharmaceutical industry

Management will also be available for virtual 1x1 meetings during the conference.

Key Points: 
  • Management will also be available for virtual 1x1 meetings during the conference.
  • If you would like to request a meeting, please contact Cantor Fitzgerald directly.
  • Further information regarding these and other risks is included in DURECT's Form 10-Q filed on July 30, 2021 under the heading "Risk Factors."
  • NOTE: POSIMIR and SABER are trademarks of DURECT Corporation.

DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit

Retrieved on: 
Wednesday, September 15, 2021
Boxed warning, Food, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Non-alcoholic fatty liver disease, Technology, AH, Patient, NASH, Company, Risk, Clinical trial, SABER, Safety, COVID-19, Calendar, Chronic liver disease, Pharmaceutical industry

If you would like to request a meeting, please contact Oppenheimer directly.

Key Points: 
  • If you would like to request a meeting, please contact Oppenheimer directly.
  • Further information regarding these and other risks is included in DURECT's Form 10-Q filed on July 30, 2021 under the heading "Risk Factors."
  • NOTE: POSIMIR and SABER are trademarks of DURECT Corporation.
  • Full prescribing information for POSIMIR, including its Boxed Warning, can be found at www.posimir.com .

DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference

Retrieved on: 
Tuesday, September 7, 2021

Management will also be available for virtual 1x1 meetings during the conference.

Key Points: 
  • Management will also be available for virtual 1x1 meetings during the conference.
  • If you would like to request a meeting, please contact [email protected] .
  • NOTE: POSIMIR and SABER are trademarks of DURECT Corporation.
  • Full prescribing information for POSIMIR, including its Boxed Warning, can be found at www.posimir.com .

BWH Hotel Group President & CEO David Kong Inducted Into Business Travel Hall Of Fame

Retrieved on: 
Thursday, September 2, 2021
Aiden, Southwest Airlines, Acquisition, List of lifetime achievement awards, Trustee, GBTA, GL, Partnership, JetBlue, Emerald Group Publishing, AH, Travel, Solution, Collection, Billboard Latin Music Lifetime Achievement Award, BW, Argyle Hotel Group, Conference, Board, Chief executive officer, Concurrence, LinkedIn, University, Industry, Hilton Hotels & Resorts, American Hotel, Board of directors, Best Western, Hotel

PHOENIX, Sept. 2, 2021 /PRNewswire/ --BWH Hotel Group announced today that David Kong, President and Chief Executive Officer, will be following in the footsteps of other industry giants and will be inducted into BTN Group's Business Travel Hall of Fame later this year.

Key Points: 
  • PHOENIX, Sept. 2, 2021 /PRNewswire/ --BWH Hotel Group announced today that David Kong, President and Chief Executive Officer, will be following in the footsteps of other industry giants and will be inducted into BTN Group's Business Travel Hall of Fame later this year.
  • The Business Travel Hall of Fame established in 2011, honors distinguished business travel leaders that have had a profound impact on the travel category.
  • "His work to transform BWH Hotel Group into a global powerhouse has undoubtedly forever changed the landscape of the travel industry.
  • "I am deeply honored to be recognized by BTN Group and inducted into the Business Travel Hall of Fame," said Kong.

National Advertising Division Finds Butterball's Qualified "All Natural" Claims Supported; Recommends Certain Other Claims be Modified or Discontinued

Retrieved on: 
Tuesday, August 10, 2021
Well, AH, Better Business Bureau, Industry, Certification, EPA, Health, Humanity (virtue), Advertising, Farmer, Animal, Hormone, Program, Animal Outlook, Council, Ren, Association of National Advertisers, CARU, NAD, Policy, LLC, Environment, Privacy, Turkey (bird), Multimedia, Steroid, Dietary supplement, Animal husbandry, Pharmaceutical industry, Renewable energy, Perfume, Marketing, Poultry, Agriculture, Online shopping

"Humane" claims that were couched in comparative, superlative or absolute terms, including:

Key Points: 
  • "Humane" claims that were couched in comparative, superlative or absolute terms, including:
    "Does Butterball Treat Its Turkeys Humanely?
  • During the proceeding, Butterball permanently discontinued the challenged headline claim "Healthy, Natural Turkeys" and permanently modified the challenged "FARM TO FAMILY" video.
  • In reliance on the advertiser's written representation that it has permanently modified these challenged claims, NAD did not review these claims on their merits.
  • About BBB National Programs:BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.